

FREE SAMPLE · VERSION 1.4


Non-Confidential Asset Summary Kit

One slide, three views: the editable template, the finished worked example, and the speaker note that explains how its first draft was revised.

SLIDE 07 · EVIDENCE SUMMARY

THE FULL KIT

Editable template (19 slides) · completed worked example (19 slides, PowerPoint and PDF, with speaker notes) · user guide (11 pages)



Slide 7 as you receive it: a prompt in every box

EVIDENCE SUMMARY

[What the public evidence shows — enough to justify a deeper look]

EVIDENCE FIGURE

[Insert one figure that is already public or approved for release: a published chart, poster figure or summary table.]

[Source: publication, poster or press release — with date]

[STATUS]

TARGET VALIDATION

[Evidence linking target or signal to disease biology]

[STATUS]

ACTIVITY SIGNAL

[In vitro, in vivo, translational or clinical activity]

[STATUS]

SAFETY / FEASIBILITY

[Safety margin, tolerability, manufacturability]

[Company name] · Non-confidential

7


WHAT YOU ARE LOOKING AT

Each bracket tells you what the box must say, and the speaker notes in PowerPoint explain the purpose of the slide, how to fill it and what to avoid. Status cells start as a prompt, so no evidence level is pre-filled for you.

The same slide, finished for a fictional company

EVIDENCE SUMMARY

Published Phase 1 data show colon exposure 29 to 34 times plasma exposure



SUPPORTED

TARGET VALIDATION

Pathway activity in UC mucosa (published human tissue studies).

SUPPORTED

ACTIVITY SIGNAL

Biopsy marker reduced at 200–400 mg in healthy volunteers.

DEMONSTRATED

SAFETY / FEASIBILITY

No dose-limiting toxicity up to 400 mg once daily.

Worked example · Corvane Therapeutics is a fictional company; all data are illustrative · Non-confidential

7

WHAT YOU ARE LOOKING AT

The worked example is a complete deck for Corvane Therapeutics, a fictional company with illustrative data. Every slide has a speaker note on why it is written the way it is; five key slides also show the first draft and the revision.

Why slide 7 reads the way it does

WHAT THIS SLIDE DOES

Gives one public figure and three tagged points, enough to justify a meeting rather than a data review.

FIRST DRAFT

"Published Phase 1 data show colon exposure more than 30 times plasma exposure."

REVISED

"Published Phase 1 data show colon exposure 29 to 34 times plasma exposure."

WHY

The chart sits next to the title, and its 400 mg bar reads 29. BD readers check titles against figures within seconds, and rounding up is the cheapest way to lose credibility on the first data slide. Quoting the range costs nothing, because 29 to 34 is still a strong result. The activity card got the same treatment: the biopsy marker was measured in healthy volunteers, so it is Supported, not Demonstrated.

Check your own slide: Read the title, then look only at the figure. Does any number in the title fall outside what the figure shows?

See everything in the kit: narralect.com/toolkits/non-confidential-asset-summary-kit